Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study
Objectives. Assessing the effectiveness and tolerability of medical cannabis (MC) treatment on Gilles de la Tourette syndrome (GTS) patients. Methods. We report on an open-label, prospective study on the effect of MC on adult GTS patients. MC mode of use was decided by the treating neurologist and t...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Behavioural Neurology |
| Online Access: | http://dx.doi.org/10.1155/2022/5141773 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564515381706752 |
|---|---|
| author | Saar Anis Corinne Zalomek Amos D. Korczyn Alina Rosenberg Nir Giladi Tanya Gurevich |
| author_facet | Saar Anis Corinne Zalomek Amos D. Korczyn Alina Rosenberg Nir Giladi Tanya Gurevich |
| author_sort | Saar Anis |
| collection | DOAJ |
| description | Objectives. Assessing the effectiveness and tolerability of medical cannabis (MC) treatment on Gilles de la Tourette syndrome (GTS) patients. Methods. We report on an open-label, prospective study on the effect of MC on adult GTS patients. MC mode of use was decided by the treating neurologist and the patient. Δ9-Tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) content within MC product and monthly dose were titrated during the study. Following treatment initiation, patients were assessed after 4 and 12 weeks for efficacy, tolerability, and side effects. Results. Eighteen patients entered the study. Baseline Yale Global Tic Severity Scale- (YGTSS) Total (range 0-100) was 60.3±17.1. Three patients did not reach the end of follow-up period. The most common mode of administration was smoking (80%). Following twelve weeks of treatment, a significant 38% average reduction (p=0.002) of YGTSS-Total and a 20% reduction (p=0.043) of Premonitory Urge for Tic Scale (PUTS) were observed. Common side effects were dry mouth (66.7%), fatigue (53.3%), and dizziness (46.7%). Three patients suffered from psychiatric side effects including worsening of obsessive compulsive disorder (stopped treatment), panic attack, and anxiety (resolved with treatment modification). Six patients (40%) reported cognitive side effects regarding time perception, visuospatial disorientation, confusion, slow processing speed, and attention. Conclusions. MC treatment demonstrates good efficacy and tolerability in adult GTS patients. Predilection for smoking rather than using oil drops requires further comparative studies to evaluate the efficacy of each. Cognitive and psychiatric side effects have to be monitored and addressed. |
| format | Article |
| id | doaj-art-fe9537cbe84e45159b40317702993e43 |
| institution | Kabale University |
| issn | 1875-8584 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Behavioural Neurology |
| spelling | doaj-art-fe9537cbe84e45159b40317702993e432025-02-03T01:10:58ZengWileyBehavioural Neurology1875-85842022-01-01202210.1155/2022/5141773Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective StudySaar Anis0Corinne Zalomek1Amos D. Korczyn2Alina Rosenberg3Nir Giladi4Tanya Gurevich5Movement Disorder UnitSackler School of MedicineSackler School of MedicineSchool of Public HealthMovement Disorder UnitMovement Disorder UnitObjectives. Assessing the effectiveness and tolerability of medical cannabis (MC) treatment on Gilles de la Tourette syndrome (GTS) patients. Methods. We report on an open-label, prospective study on the effect of MC on adult GTS patients. MC mode of use was decided by the treating neurologist and the patient. Δ9-Tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) content within MC product and monthly dose were titrated during the study. Following treatment initiation, patients were assessed after 4 and 12 weeks for efficacy, tolerability, and side effects. Results. Eighteen patients entered the study. Baseline Yale Global Tic Severity Scale- (YGTSS) Total (range 0-100) was 60.3±17.1. Three patients did not reach the end of follow-up period. The most common mode of administration was smoking (80%). Following twelve weeks of treatment, a significant 38% average reduction (p=0.002) of YGTSS-Total and a 20% reduction (p=0.043) of Premonitory Urge for Tic Scale (PUTS) were observed. Common side effects were dry mouth (66.7%), fatigue (53.3%), and dizziness (46.7%). Three patients suffered from psychiatric side effects including worsening of obsessive compulsive disorder (stopped treatment), panic attack, and anxiety (resolved with treatment modification). Six patients (40%) reported cognitive side effects regarding time perception, visuospatial disorientation, confusion, slow processing speed, and attention. Conclusions. MC treatment demonstrates good efficacy and tolerability in adult GTS patients. Predilection for smoking rather than using oil drops requires further comparative studies to evaluate the efficacy of each. Cognitive and psychiatric side effects have to be monitored and addressed.http://dx.doi.org/10.1155/2022/5141773 |
| spellingShingle | Saar Anis Corinne Zalomek Amos D. Korczyn Alina Rosenberg Nir Giladi Tanya Gurevich Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study Behavioural Neurology |
| title | Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study |
| title_full | Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study |
| title_fullStr | Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study |
| title_full_unstemmed | Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study |
| title_short | Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study |
| title_sort | medical cannabis for gilles de la tourette syndrome an open label prospective study |
| url | http://dx.doi.org/10.1155/2022/5141773 |
| work_keys_str_mv | AT saaranis medicalcannabisforgillesdelatourettesyndromeanopenlabelprospectivestudy AT corinnezalomek medicalcannabisforgillesdelatourettesyndromeanopenlabelprospectivestudy AT amosdkorczyn medicalcannabisforgillesdelatourettesyndromeanopenlabelprospectivestudy AT alinarosenberg medicalcannabisforgillesdelatourettesyndromeanopenlabelprospectivestudy AT nirgiladi medicalcannabisforgillesdelatourettesyndromeanopenlabelprospectivestudy AT tanyagurevich medicalcannabisforgillesdelatourettesyndromeanopenlabelprospectivestudy |